P/B
2,5
AN2 Therapeutics
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
$190.6M
Market Cap • 9/18/2026
2017
(9 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,2
EPS
—
Market Cap
Market Cap
190,6M
EV
112,2M
EV/Revenue
0
EV/EBITDA
-2,9
EV/EBIT
-2,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-20,5%
Total Yield
-20,5%
Payout
0%
Retained Earnings
-259,2M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2
Debt/Equity
0%
Current Ratio
14,3
Quick Ratio
14
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!